Sanofi SA vs Zscaler Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Zscaler Inc trades at $148.6 (market cap $24.23B). The key difference: Sanofi SA is far larger — about 4.3× Zscaler Inc's market cap, and Sanofi SA pays a 5.5% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| SNY | ZS | |
|---|---|---|
Market Cap | $104.83B | $24.23B |
Sector | Health | Technology |
52-Week High | $52.34 | $336.27 |
52-Week Low | $41.33 | $118.05 |
Enterprise Value | $121.32B | $22.55B |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →